Dopamine receptor modulation by conformationally constrained analogs of Pro-Leu-Gly-NH2
- 1 July 1988
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 31 (7) , 1430-1436
- https://doi.org/10.1021/jm00402a031
Abstract
Two series of conformationally constrained analogues of Pro-Leu-Gly-NH2 (PLG) have been synthesized. In one series of analogues, the Leu-Gly-NH2 dipeptide segment of PLG was replaced with the .gamma.-lactam residues 3(S)- and 3(R)-amino-2-oxopyrrolidineacetamide and the .delta.-lactam residue 3(S)-amino-2-oxopiperidineacetamide. The corresponding .gamma.-lactam analogues of < Glu-Leu-Gly-NH2 were also synthesized. In a second series of analogues, the glycinamide residue of PLG was replaced with the 2-ketopiperazine, 3(S)-amino-2-pyrrolidone, and 3(S)-amino-2-piperidone residues. The above analogues were tested for their ability to enhance the binding of the dopamine receptor agonist 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) to striatal dopamine receptors. Of the conformationally constrained analogues of PLG synthesized in this study, only the .gamma.-lactam analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide (3) was found to possess significant activity. This analogues was 10,000 times more active than PLG, under preincubation conditions. It significantly enhanced the binding of ADTN at concentrations of 10-9 and 10-10 M.This publication has 11 references indexed in Scilit:
- Synthesis of Pro-Leu-Gly-NH2 analogs modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTNJournal of Medicinal Chemistry, 1986
- Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogs possessing cyclic amino acid residues at the C-terminal positionJournal of Medicinal Chemistry, 1986
- Effect of Chronic Treatment with Morphine on the Binding of 3H-N-n-Propylnorapomorphine to Striatal Membranes of Rats: Influence of Prolyl-Leucyl-GlycinamidePharmacology, 1985
- The effect of melanotropin release inhibiting factor, its metabolites and analogs on [3H]spiroperidol and [3H]apomorphine binding sitesGeneral Pharmacology: The Vascular System, 1982
- Conformational energy analysis of melanostatinInternational Journal of Peptide and Protein Research, 1982
- Protected lactam-bridged dipeptides for use as conformational constraints in peptidesThe Journal of Organic Chemistry, 1982
- Neuroleptic Drug-Induced Dopamine Receptor Supersensitivity: Antagonism by L-Prolyl-L-Leucyl-GlycinamideScience, 1981
- Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindingsPeptides, 1981
- Melanostatin conformations in solutionBiopolymers, 1979
- Study of the structural requirements for Dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamideJournal of Medicinal Chemistry, 1978